Outlook Therapeutics, Inc.
OTLK
$1.37
-$0.02-1.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 17.38M | 5.69M | 44.41M | -114.29M | -11.18M |
| Total Depreciation and Amortization | 28.80K | 28.80K | 28.70K | 28.20K | 28.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.26M | -26.92M | -62.17M | 96.25M | 2.32M |
| Change in Net Operating Assets | 6.89M | 4.22M | -1.78M | -1.26M | -4.20M |
| Cash from Operations | -10.97M | -16.98M | -19.51M | -19.27M | -13.03M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | -1.10K | -3.20K |
| Issuance of Common Stock | 1.74M | -- | 4.31M | 56.14M | -- |
| Repurchase of Common Stock | -- | -115.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.74M | -115.00K | 4.31M | 56.14M | -3.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.23M | -17.10M | -15.20M | 36.87M | -13.04M |